UK National Institute for Health and Clinical Excellence evidence based guidelines on Pneumonia; Diagnosis and management of community and hospital acquired pneumonia in adults.
European Respiratory Society (ERS) and European Society of Clinical Microbiology and Infectious Diseases evidence-based recommendations for the most common management questions occurring in routine clinical practice in the management of adult patients with LRTI.
British Thoracic Society guidelines for the management of community acquired pneumonia in children: update 2011
An Official ATS Workshop Report: Emerging Issues and Current Controversies in HIV-Associated Pulmonary Diseases
An Official American Thoracic Society Statement: Treatment of Fungal Infections in Adult Pulmonary and Critical Care Patients
The Management of Community-Acquired Pneumonia in Infants and Children Older Than 3 Months of Age: Clinical Practice Guidelines by the Pediatric Infectious Diseases Society and the Infectious Diseases Society of America
World Health Organisation (WHO) guidelines for the pharmacological management of pandemic Influenza A (H1N1) other Influenza Viruses: Recommendations
British Thoracic Society Guidelines for the management of community acquired pneumonia in adults
UK National Institute of Health and Clinical Excellence (NICE) recommends Oseltamivir and Zanamivir for the treatment of influenza in adults and children if influenza virus A or B is circulating, the person is in an ‘at-risk’ group, the person presents with an influenza-like illness and can start treatment within 48 hours (or within 36 hours for zanamivir treatment in children) of the onset of symptoms.
Defining, treating and preventing hospital acquired pneumonia: European perspective produced by the European Respiratory Society (ERS), European Society of Clinical Microbiology and Infectious Diseases and the European Society of Intensive Care Medicine.
World Health Organisation revised guidance on the clinical management of human infection with pandemic (H1N1)